Brain Differences in Infants at Differential Genetic Risk for Late-Onset Alzheimer Disease
A Cross-sectional Imaging Study

Douglas C. Dean III, MSc; Beth A. Jerskey, PhD; Kewei Chen, PhD; Hillary Protas, PhD; Pradeep Thiyyagura, MS; Auttawat Roontiva, MS; Jonathan O’Muireachtaigh, PhD; Holly Dirks, BSc; Nicole Waskiewicz, BSc; Katie Lehman, BSc; Ashley L. Sinardi, PhD; Mari N. Turk, PhD; Xue Hua, PhD; Sarah K. Madsen, BS; Paul M. Thompson, PhD; Adam S. Fleisher, MD; Matthew J. Huentelman, PhD; Sean C. L. Deoni, PhD; Eric M. Reiman, MD

**IMPORTANCE** Converging evidence suggests brain structure alterations may precede overt cognitive impairment in Alzheimer disease by several decades. Early detection of these alterations holds inherent value for the development and evaluation of preventive treatment therapies.

**OBJECTIVE** To compare magnetic resonance imaging measurements of white matter myelin water fraction (MWF) and gray matter volume (GMV) in healthy infant carriers and noncarriers of the apolipoprotein E (APOE) ε4 allele, the major susceptibility gene for late-onset AD.

**DESIGN, SETTING, AND PARTICIPANTS** Quiet magnetic resonance imaging was performed at an academic research imaging center on 162 healthy, typically developing 2- to 25-month-old infants with no family history of Alzheimer disease or other neurological or psychiatric disorders. Cross-sectional measurements were compared in the APOE ε4 carrier and noncarrier groups. White matter MWF was compared in one hundred sixty-two 2- to 25-month-old sleeping infants (60 ε4 carriers and 102 noncarriers). Gray matter volume was compared in a subset of fifty-nine 6- to 25-month-old infants (23 ε4 carriers and 36 noncarriers), who remained asleep during the scanning session. The carrier and noncarrier groups were matched for age, gestational duration, birth weight, sex ratio, maternal age, education, and socioeconomic status.

**MAIN OUTCOMES AND MEASURES** Automated algorithms compared regional white matter MWF and GMV in the carrier and noncarrier groups and characterized their associations with age.

**RESULTS** Infant ε4 carriers had lower MWF and GMV measurements than noncarriers in precuneus, posterior/middle cingulate, lateral temporal, and medial occipitotemporal regions, areas preferentially affected by AD, and greater MWF and GMV measurements in extensive frontal regions and measurements were also significant in the subset of 2- to 6-month-old infants (MWF differences, $P < .05$, after correction for multiple comparisons; GMV differences, $P < .001$, uncorrected for multiple comparisons). Infant ε4 carriers also exhibited an attenuated relationship between MWF and age in posterior white matter regions.

**CONCLUSIONS AND RELEVANCE** While our findings should be considered preliminary, this study demonstrates some of the earliest brain changes associated with the genetic predisposition to AD. It raises new questions about the role of APOE in normal human brain development, the extent to which these processes are related to subsequent AD pathology, and whether they could be targeted by AD prevention therapies.

Published online November 25, 2013.
What are the earliest brain changes associated with the predisposition to Alzheimer disease (AD)? The amyloid cascade hypothesis suggests that AD begins with accumulation of β-amyloid 1-42 (Aβ1-42) proteins into oligomeric and fibrillar assemblies, leading to neuroinflammatory changes, accumulation, propagation, and phosphorylation of the microtubule-associated protein tau, and dysfunction and loss of synapses and neurons. While cerebral Aβ deposition may begin 1 to 2 decades prior to the onset of cognitive impairment, recent studies suggest functional and structural brain alterations may precede the onset of Aβ deposition in carriers of the apolipoprotein E (APOE) ε4 allele, the major late-onset AD susceptibility gene, and in carriers of a rare early-onset autosomal dominant AD mutation. These findings have led us to explore even earlier brain differences in individuals at differential genetic risk of AD.

The APOE ε4 allele is found in about one-quarter of the population and about 60% of patients with AD dementia. Each additional copy of the ε4 allele in a person's APOE genotype is associated with a heightened risk of AD and an earlier average age at dementia onset. In a positron emission tomography study, we have previously shown that young adult APOE ε4 carriers have lower cerebral metabolic rates of glucose than noncarriers in brain regions preferentially affected by AD, almost 5 decades before their average age at possible dementia onset. While carriers did not have greater age-related cerebral metabolic rates of glucose decline than noncarriers between young adulthood and late middle age, the metabolic reductions were located in regions preferentially and progressively affected by metabolic decline and amyloid deposition in the later preclinical and clinical stages of AD. In a subsequent postmortem study, we and our colleagues found that young adult APOE ε4 carriers had less cytochrome-c oxidase activity (a measure of oxidative metabolism) in brain tissue from the posterior cingulate (one of the regions preferentially affected by AD), even in the absence of soluble or fibrillar Aβ.

These findings, as well as those from other structural, functional, and functional connectivity magnetic resonance imaging (MRI) studies of older children and young adults at differential genetic risk for AD, led us to postulate that APOE ε4 carriers have neurodevelopmental alterations that provide a foothold for the neuropathological changes associated with the subsequent course of AD. Indeed, researchers recently used volumetric MRI to explore differences in regional gray matter volume (GMV) in 1- to 3-month-old carriers and noncarriers of the APOE ε4 allele (as well as in carriers and noncarriers of 4 other genes implicated in the predisposition to several psychiatric disorders) who were enriched for a reported parental history of psychiatric disorders and use of psychotropic medications. Additional studies are needed to extend APOE ε4-related GMV findings to healthy infants without a parental history of psychiatric or neurological disorders or medication use, including other brain imaging measurements and infants from a broader age range, and clarify the extent to which these measurements change during the course of brain development.

In this cross-sectional brain imaging study, we sought to characterize and compare regional MWF and a white matter myelin content measure in healthy infant ε4 carriers and noncarriers 2 to 25 months of age. To do so, we used unusually quiet MRI techniques that were developed specifically for the study of naturally sleeping infants and toddlers. A T1-weighted volumetric MRI scan was used to assess regional GMV. An imaging technique called mcDESPOT (multi-component Driven Equilibrium Single Pulse Observation of T1 and T2) was used to assess regional myelin water fraction (MWF), a quantitative measure sensitive to myelin that we have previously used to investigate infant brain development and demyelinating disorders such as multiple sclerosis. Prior mcDESPOT investigations of white matter development throughout infancy and early childhood have mirrored the histologically established spatiotemporal pattern of myelination, and histological comparisons in a dysmyelinating “shaking-pup” model have demonstrated the method’s sensitivity and specificity to detect myelin. Automated voxel-based image-analysis algorithms were used to compare regional MWF and GMV to characterize and compare age-related trajectories in the 2- to 25-month-old ε4 carrier and noncarrier groups.

Methods

Study Design and Participants

Data from 162 healthy, typically developing, 2- to 25-month-old infants were included in this study. All participants and families were recruited from the local area via pamphlets and flyers at community events, parks, day care centers, play centers, etc. To help mitigate potential confounds beyond APOE genotype, rigorous selection criteria included the following: healthy singleton birth between 37 and 42 weeks’ gestation; APGAR score of at least 8; no abnormalities on fetal ultrasound; no reported history of neurological events or disorders in the infant (ie, head trauma, ischemia, or epilepsy, for example); no complications (ie, pre-eclampsia) during pregnancy; and no reports of illicit drug or alcohol use during pregnancy. These criteria were confirmed during parental interviews at the time of enrollment. Extensive infant, parent, and sibling medical and family history questionnaires were also used to provide information about the prospectives infants’ neurological, psychiatric, and other medical events and disorders; maternal and paternal education levels; maternal prenatal and postnatal health, substance use, and breastfeeding practices; gestation duration; and birth weight. Written informed consent was obtained from each infant’s parents or legal guardian, and the study was performed under guidelines approved by the Brown University institutional review board. Parents were not informed of their child’s APOE genotype, in accordance with the informed consent and institution’s institutional review board policies.

Data were used as follows to characterize and compare regional MWF and GMVs in infant ε4 carrier and noncarrier groups. (1) The MWF images from one hundred sixty-two 2-
Brain Differences in Infants at Risk for AD

Regional MWF Comparisons

The MWF maps were calculated for each of the 162 infants and coregistered to a common template using the Advanced Normalization Tools software package. 26-28 To derive the MWF measures, the individual SPGR, IR-SPGR, and balanced SSFP images were first linearly coregistered to account for subtle intrascan head motion, 29 and nonparenchymal signal was removed from each image using an automated deformable model approach. 30 The IR-SPGR images were used in conjunction with the SPGR images to correct for transmit (B1) magnetic field inhomogeneities, while main magnetic field inhomogeneities were corrected by acquiring the balanced SSFP images with 2 phase-cycling schemes. 31 The MWF maps were then derived by fitting the SPGR and balanced SSFP images to a 3-pool, multicomponent relaxation model. 25

To align each infant’s mcDESPOT MWF map to a common analysis space, the high-flip angle SPGR image was first nonlinearly registered to an age-specific template. Using this nonlinear transformation as well as previously calculated transformations 18 from the age-specific templates to a higher-level template (that had been rigidly coregistered to the Montreal Neurological Institute T1-weighted template), the quantitative MWF maps were transformed into the space of the study template.

Regional MWF comparisons were performed using the full cohort of 2- to 25-month-old infants to characterize early developmental differences between carriers and noncarriers. To
identify the earliest changes, this analysis was repeated using a subset of thirty-six 2- to 6-month-old infants. Data were smoothed with a modest 2.5-mm full-width-at-half-maximum gaussian kernel and the voxelwise unpaired \( t \) tests were performed via nonparametric permutation testing using the Randomize module of the FMRIB Software Library (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/). We chose 2.5-mm smoothing based on the relative size of the infant and toddler head, as well as to maintain the fidelity of the underlying imaging data.

Significance was defined as \( P < .05 \) corrected for multiple comparisons using a cluster-based technique, a commonly used multiple testing method for determining corrected significances while accounting for the high level of spatial dependencies between adjacent voxels.\(^{32}\) Contiguous clusters were first identified using a threshold of \( P < .005 \) (\( t > 3.1 \)). For visualization purposes, the statistical brain maps were superimposed sections from the spatial standardized volume-rendered brain MRI of a healthy 12-month-old infant (Figure 2). As previously noted, T1-weighted MRIs from the twenty-two 2- to 6-month-old infants were excluded from the GMV analysis because of an inability of the automated algorithm to generate adequate segmented gray matter images in 9 of these infants.

Regional GMV Comparison

For the 6- to 22-month-old infants with high-resolution volumetric T1-weighted MRIs, the VBM8 toolbox in the SPM8 brain-mapping platform\(^{33}\) was used to generate segmented gray matter images, deform each image to the coordinates of a standardized brain atlas using an infant MRI template (to which the quality of the gray matter segmentation was semiquantitatively checked), smooth the spatially normalized gray matter maps with an 8-mm full-width-at-half-maximum gaussian kernel, and use a voxelwise general linear model to characterize between-group difference in regional GMV between the 23 \( \varepsilon_4 \) carriers and 36 noncarriers \( (P < .001, \text{uncorrected for multiple comparisons}) \). The false discovery rate sub-routine was used to assess significance after correction for multiple regional comparisons. For visualization purposes, the statistical brain map was superimposed onto the spatial standardized volume-rendered brain MRI of a healthy 12-month-old infant (Figure 3). As previously noted, T1-weighted MRIs from the twenty-two 2- to 6-month-old infants were excluded from the GMV analysis because of an inability of the automated algorithm to generate adequate segmented gray matter images in 9 of these infants.

Associations Between Brain Imaging Measurements and Age

In subsequent analyses, we characterized and compared relationships between brain imaging measures and age in the \( \varepsilon_4 \) carrier and noncarrier groups (Figure 4). Logarithmic developmental trajectories \( \text{MWF} \text{(age)} = A \times \log \text{(age)} - B \) were used to characterize and compare associations between regional MWF and age in each group (A). A bootstrap fitting approach with residual resampling\(^{34}\) was used to fit 750 curves in each group at each image voxel, and the resulting trajectory distributions were compared using an unpaired \( t \) test with cluster-based correction for multiple comparisons as described earlier. To explore associations between regional GMV and age, individual infant measurements were extracted from the precuneus, precuneus/cingulate, lateral temporal, medial occipitotemporal, and frontal atlas locations in Table 1 that were associated with maximally significant between-group differences in regional GMV. These data were used to perform linear regressions between regional GMV and age and to characterize and compare linear slopes in the \( \varepsilon_4 \) carrier and noncarrier groups. While the analysis of age-related MWF change used a logarithmic trajectory, a linear trajectory model was used to confirm the logarithmic findings and compare the 2 fits. We
also confirmed our bootstrap analysis by examining the voxelwise log(age) × ε3/ε4 group interaction.

Results

Groups

As previously noted, MWF images from 162 infants, 2 to 25 months of age, including 60 ε4 carriers and 102 noncarriers, were used to assess regional white matter myelin content. T1-weighted volumetric images from 59 of the infants, 6 to 22 months of age, including 23 ε4 carriers and 36 noncarriers, were used to assess regional GMV. T1-weighted volumetric images were not available in 81 of the other 6- to 25-month-old infants, including 30 ε4 carriers and 51 noncarriers who awakened prior to completion of the latter scan. (There were no significant differences between the proportions of ε4 carriers and noncarriers in the 6- to 25-month-old groups with and without available T1-weighted volumetric images.)

Contrast between gray and white matter was insufficient to generate adequate segmented gray matter images in 9 of the 22 infants younger than 6 months, including 5 of the 7 ε4 carriers and 4 of the 15 noncarriers during the automated image-analysis algorithm’s initial preprocessing stage. For this reason, T1-weighted MRIs from all 22 of the infants younger than 6 months were excluded from the GMV analysis to eliminate the potential for differential selection bias in the youngest infant carrier and noncarrier groups. The fact that insufficient contrast between gray matter and white matter was observed only in some of the youngest infants and in a higher proportion of ε4 carriers than noncarriers (χ², P = .047) could reflect less myelin content in the youngest infant age range, particularly in the carrier group. This possibility is supported by the mcDESPOT-generated MWF findings given later.

Characteristics and additional demographic features of the infant ε4 carrier and noncarrier groups in each comparison are shown in Table 2 and Table 3. Infant APOE ε4 carrier and noncarrier groups in the respective 2- to 25-month-old MWF, 2- to 6-month-old MWF, and 6- to 22-month-old GMV comparisons did not differ significantly in their age (corrected for 40-week gestation), birth weight, maternal age, socioeconomic status, educational level, male-female ratio, breastfed to bottle-fed ratio, reported in utero alcohol exposure, vaginal to cesarean birth ratio, or parental marital status.

2- to 25-Month-Old and 2- to 6-Month-Old MWF Comparisons

Differences between the infant APOE ε4 carrier and noncarrier groups in regional MWF, including those in the entire 2- to 25-month-old cohort and those in the 2- to 6-month-old subset, are shown in Figure 2 and Table 1. Compared with noncarriers, the 2- to 25-month-old ε4 carriers had significantly lower MWF in posterior white matter regions, including the optic radiations, corticospinal tracts, and splenium of the corpus callosum (P < .001, uncorrected for multiple comparisons). The magnitude and atlas locations of maximally significant differences in regional MWF are shown in Table 1.
pallose lumen; they also had significantly greater MWF in frontal white matter regions, including the corona radiata, genu of the corpus callosum, and orbitofrontal cortex. The posterior MWF reductions and MWF increases remained significant in the comparison of ε4 carriers and noncarriers younger than 6 months.

6- to 22-Month-Old GMV Comparison

Differences between the 6- to 22-month-old APOE ε4 carrier and noncarrier groups in regional GMV are shown in Figure 3 and Table 1. Compared with noncarriers, 6- to 22-month-old ε4 carriers had reduced GMVs in the bilateral precuneus, posterior/middle cingulate, and occipitotemporal and left lateral temporal regions, which are preferentially affected in the later preclinical and clinical stages of Alzheimer disease, and significantly greater GMVs (in red) in bilateral medial and lateral frontal regions (P < .001, uncorrected for multiple comparisons). Statistical maps are projected onto the medial and lateral surfaces of a spatially standardized 12-month-old infant’s brain. The magnitude and atlas locations of maximally significant differences in regional GMV are shown in Table 1.

Associations Between Brain Imaging Measurements and Age

As shown in Figure 4, there were highly significant associations (P < .001, cluster-corrected for multiple comparisons) between MWF and age in the 2- to 25-month-old ε4 carrier and noncarrier groups. Compared with noncarriers, ε4 carriers had a significantly attenuated relationship between MWF and age (ie, reduced MWF development rate) in extensive white matter locations, including optic radiations, corticospinal tracts, and splenium of the corpus callosum. Compared with noncarriers, ε4 carriers also had significantly stronger relationships between MWF and age in more restricted locations, including frontal and association white matter regions and those that have been previously shown to be associated with APOE genotype (ε4ε4 or ε4ε4 > ε3ε3 > ε2ε3) in cognitively unimpaired older adults.36 (As expected, logarithmic and linear models yielded nearly identical relationships between mean MWF and age, but the logarithm model was able to do so with greater statistical power [eg, logarithmic r² of 0.86 vs linear r² of 0.69 in corpus callosum regions of interest, 0.83 vs 0.76 frontal white matter regions of interest, and 0.84 vs 0.72 in cerebellar white matter regions of interest].) Results from the bootstrap analysis were supported by more conventional log(age) vs group interaction analysis, which provided similar results (not shown).

Of interest, areas showing greater MWF development in the ε4 carriers vs noncarriers were found to lie preferentially along the white matter/gray matter boundaries. A possible reason for this is partial-volume effects within these regions. However, the white matter/gray matter boundary is continuously evolving over this age range, as both white matter and gray matter myelinate, and thus, this finding could relate to myelin development differences within gray matter.

Only 1 location associated with maximally significant GMV differences in the 5- to 22-month-old ε4 carrier and noncarrier groups (Table 1) was found to have a significant association with age in either of the subject groups: GMVs in the left
Precuneus were inversely associated with age in the noncarriers ($r = -0.58; P = .0002; P = .002$ after Bonferroni correction), but not in the ε4 carriers ($r = 0.022, P = .92$). While the inverse association was greater in the carriers than noncarriers ($P = .02$), this finding did not survive correction for multiple comparisons, could well reflect type I error, and would need to be confirmed in further independent studies.

**Discussion**

While our findings should be considered preliminary, this study demonstrates some of the earliest brain changes associated with the major genetic risk factor for late-onset AD. Infant ε4 carriers had lower MWF and GMV measurements than noncarriers in the precuneus, posterior/middle cingulate, lateral temporal, and medial occipitotemporal regions, which are preferentially affected by AD, and greater MWF and GMV measurements in frontal regions. The MWF findings remained significant in the subset of 2- to 6-month-old infants. Infant ε4 carriers also exhibited an attenuated relationship between MWF and age in extensive (including earlier developing, posterior) white matter regions and a stronger relationship in more restricted, later developing frontal and associated white matter regions.

As part of a broader effort to characterize regional GMV differences in infant carriers and noncarriers of genetic variants that have been implicated in the predisposition to several psychiatric disorders, Knickmeyer and colleagues recently compared MRIs from 66 APOE ε4 carriers and 156 noncarriers 1 to 3 months of age. Many of the infants had a parental psychiatric history and a past parental substance use disorder history, many were monozygotic or dizygotic twins, and a different image-analysis technique was used to compare GMV in the carrier and noncarrier groups. By comparison, our study compared regional GMVs in 6- to 22-month-old singleton infant ε4 carriers and noncarriers without a parental history of psychiatric disorders, neurological disorders, or medication use, it compared a measure of regional white matter myelin content in 2- to 25-month-old carriers and noncarriers, and it investigated their relationship to brain development over these broader age ranges.
In comparison with noncarriers, ε4 carriers in the Knickmeyer et al study had lower GMV in lateral and medial temporal, occipitotemporal, frontal, and precuneus regions and greater GMV in posterior parietal, occipital, middle cingulate, and other frontal and precuneus regions. Some of their ε4-related findings in the 2 studies are similar (posterior parietotemporal, occipitotemporal, and precuneus locations and frontal increases), other differences appear to be directly opposing (ie, increases in other precuneus locations in the prior study), and other differences were in reported in only 1 of the 2 studies. Differences in the reported GMV findings could be attributable to differences in infant age, inclusion criteria, image acquisition, or image analysis, limited statistical power, or our decision to restrict the analysis to infants with adequate segmented gray matter images, as noted later. In contrast to the study by Knickmeyer and colleagues, our GMV analysis excluded infants younger than 6 months from the GMV analysis because of the inability of our automated image-analysis algorithm to generate adequate segmented gray matter images in 9 of the 22 infants, including a higher proportion of ε4 carriers than noncarriers. Our mcDESPOT MWF findings suggest that this failure may be related to insufficient myelination in the youngest infants, particularly in those with the ε4 allele. Despite the study differences, the 2 studies provide a foundation for investigating the earliest postnatal neurodevelopmental changes associated with the differential genetic risk for AD and the role of the APOE allele on white and gray matter development.

While we cannot exclude the possibility completely, regional GMV differences in the 6- to 25-month-old infants do not seem to be solely attributable to differences in gray matter–white matter contrast (eg, a potential overestimation of GMV of gray matter in locations with less myelination). The automated image-analysis algorithm generated adequately segmented gray matter images in all of the infants in this age group, ε4-related GMV reductions coincided with white matter MWF reductions (not increases) in posterior regions, and ε4-related GMV increases coincided with MWF increases (not reductions) in frontal regions.

The APOE protein participates in the transport and clearance of cholesterol, which could have effects on the development, maintenance, and repair of synapses and myelinated neurons.37 APOE isoforms differ in the extent to which they are expressed (ε2 > ε3 > ε4) and folded, perhaps accounting for differential effects on Aβ accumulation and clearance, brain metabolism, tau dephosphorylation, inflammation, neuronal plasticity and repair, other physiological processes, brain development, and the risk of AD. Additional studies are needed to clarify the role of APOE in neuronal, synaptic, and myelin development, whether and how APOE isoforms may influence
ence these neurodevelopmental processes, and whether and how these neurodevelopmental processes may be relevant to the subsequent development of AD and whether these neurodevelopmental processes are affected by any of the other genetic risk factors for AD.

We have previously postulated that young adults at genetic risk for AD have a reduction in the density, activity, or metabolism of terminal neuronal fields or perisynaptic glial cells in preferentially affected brain regions, that the underlying processes provide a foothold for subsequent pathogenic changes, and that they are developmental.6,9,10 Regional GMV reductions in infant ε4 carriers are at least partly consistent with this possibility. The ε4-related increases in frontal GMV and MWF increases are more difficult to understand at this time.

In an MRI study of healthy older adults, Bartzokis and colleagues36 found that APOE variants (ε4 > ε3 > ε2) were associated with a steeper rate of myelin breakdown in late-myelinating frontal regions and that APOE-mediated myelin development, maintenance, and repair mechanisms may contribute to the predisposition to AD. Interestingly, our study found that infant ε4 carriers had greater MWF in relatively late-maturing frontal white matter regions, less MWF in relatively early-maturing posterior white matter regions, and an attenuated relationship between MWF and age during the course of infant development. The current study raises new questions about the role of APOE in myelin development, the influence of APOE variants on this process, and the extent to which myelin development contributes to the predisposition to AD.

Studies have not yet resolved whether cognitive impairment is slightly better, slightly worse, or completely unaffected in infants, children, adolescents, and young adults with and without the APOE ε4 allele. According to a recent meta-analysis of studies in children, adolescents, and young adults, Ihle and colleagues38 reported the following. Several small studies (as well as a small study assessing mental development in 24-month-old infants39) have suggested slightly better cognitive performance in noncarriers in ε4 carriers, particularly on executive tasks, leading to the idea that better executive performance and greater frontal cortex activation during associative memory tasks reflects compensatory processes. Others small studies have suggested slightly worse cognitive performance in ε4 carriers. Largest studies have failed to detect differences between carriers and noncarriers in their executive or other cognitive task performance, IQ, or educational attainment, and their meta-analysis of 20 studies involving more than 11 000 nine- to 31-year-old ε4 carriers and noncarriers failed to support a significant difference in executive or overall cognitive performance. Our findings underscore the need for larger cross-sectional and longitudinal studies to characterize and compare performance on executive and other cognitive domains starting in infancy.

### Table 2. Characteristics of the Infant Apolipoprotein E ε4 Carrier and Noncarrier Groups*

<table>
<thead>
<tr>
<th></th>
<th>ε4 Carriers</th>
<th>ε4 Noncarriers</th>
<th>P Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td>2- to 25-month-old infant regional MWF comparison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of participants</td>
<td>60</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>Genotype, No.</td>
<td>ε4ε4, ε4ε3, ε4ε2</td>
<td>ε3ε4, ε2ε4, ε2ε3, ε2ε2</td>
<td></td>
</tr>
<tr>
<td>Age, d</td>
<td>391 (196)</td>
<td>366 (181)</td>
<td>.36</td>
</tr>
<tr>
<td>Gestation, wk</td>
<td>39.8 (1.5)</td>
<td>39.6 (1.9)</td>
<td>.46</td>
</tr>
<tr>
<td>Female/male</td>
<td>25/35</td>
<td>54/48</td>
<td>.28</td>
</tr>
<tr>
<td>Maternal age, y</td>
<td>29.6 (6.1)</td>
<td>29.7 (5.2)</td>
<td>.69</td>
</tr>
<tr>
<td>Maternal SESc</td>
<td>5.7 (0.9)</td>
<td>5.7 (1.1)</td>
<td>.15</td>
</tr>
<tr>
<td>2- to 6-month-old infant regional MWF comparison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of participants</td>
<td>14</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Genotype, No.</td>
<td>ε4ε4, ε4ε3, ε4ε2</td>
<td>ε3ε4, ε2ε4, ε2ε3, ε2ε2</td>
<td></td>
</tr>
<tr>
<td>Age, d</td>
<td>118 (32)</td>
<td>127 (33)</td>
<td>.44</td>
</tr>
<tr>
<td>Gestation, wk</td>
<td>39.2 (1.2)</td>
<td>39.3 (1.3)</td>
<td>.49</td>
</tr>
<tr>
<td>Female/male</td>
<td>8/6</td>
<td>12/10</td>
<td>.49</td>
</tr>
<tr>
<td>Maternal age, y</td>
<td>32.1 (4.1)</td>
<td>30.2 (4.1)</td>
<td>.31</td>
</tr>
<tr>
<td>Maternal SESc</td>
<td>6 (1)</td>
<td>5.4 (1.2)</td>
<td>.32</td>
</tr>
<tr>
<td>6- to 22-month-old infant regional GMV comparison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of participants</td>
<td>23</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>Genotype, No.</td>
<td>ε4ε4, ε4ε3, ε4ε2</td>
<td>ε3ε4, ε2ε4, ε2ε3, ε2ε2</td>
<td></td>
</tr>
<tr>
<td>Age, d</td>
<td>399 (123)</td>
<td>414 (141)</td>
<td>.66</td>
</tr>
<tr>
<td>Gestation, wk</td>
<td>39.5 (1.2)</td>
<td>39.2 (1.3)</td>
<td>.35</td>
</tr>
<tr>
<td>Female/male</td>
<td>11/12</td>
<td>20/16</td>
<td>.60</td>
</tr>
<tr>
<td>Maternal age, y</td>
<td>30.1 (5.2)</td>
<td>29.4 (5.9)</td>
<td>.66</td>
</tr>
<tr>
<td>Maternal SESc</td>
<td>5.8 (1.2)</td>
<td>5.5 (0.9)</td>
<td>.38</td>
</tr>
</tbody>
</table>

Abbreviations: GMV, gray matter volume; MWF, myelin water fraction; SES, socioeconomic status.

a Infant ages were corrected to an estimated 40-week gestational duration.

b Groups were compared for gestational age, maternal age, and maternal SES using a 2-sample t test and for sex differences, using a χ² test.

c Maternal SES was evaluated using the Hollingshead Two-Factor Index of Social Position.35
An open question, however, remains as to the benefit of increased myelin content or faster myelin development rate at these young ages. While scant evidence exists to suggest increased myelin content directly benefits cognitive or behavioral processing, there is strong evidence for a strong spatio-temporal association between white matter myelination and behavioral maturation and that delayed myelination is associated with developmental delay.40,41

This study has several limitations. Since the reported regional GMV changes did not survive statistical correction for multiple comparisons, these findings should be considered exploratory and need to be confirmed in subsequent studies. Still, the uncorrected $P$ values exceeded a threshold ($P < .001$) that we have consistently found to optimize the trade-off between type I and type II error (because of the smaller number of independent comparisons in connected brain regions), the implicated voxel clusters were extensive and bilateral, some of the $P$ values approached $P = .00001$, and some of the $\varepsilon_4$-related regional GMV differences were reported in the prior infant MRI study. While cross-sectional analyses permitted us to characterize and compare associations between brain imaging measurements and age in the carrier and noncarrier groups, longitudinal studies are needed to characterize and compare trajectories with greater statistical power. Additional studies are needed to clarify the extent to which our $\varepsilon_4$- and age-related findings are attributable to differences in gray matter/white matter contrast.

### Conclusions

Findings from this study raise new questions about the role of $APOE$ in normal human brain development and the earliest processes involved in the predisposition to AD, their possible relationship to subsequent AD pathology, and the extent to which they can be targeted by AD prevention therapies.

### Table 3. Additional Demographic Features of the Infant Apolipoprotein E $\varepsilon_4$ Carrier and Noncarrier Groups

<table>
<thead>
<tr>
<th>No. of Participants</th>
<th>$\varepsilon_4$ Carriers</th>
<th>$\varepsilon_4$ Noncarriers</th>
<th>$P$ Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2- to 25-month-old infant regional MWF comparison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of participants</td>
<td>60</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>Child feeding (breast/bottle/both)</td>
<td>23/16/21</td>
<td>42/21/39</td>
<td>.17</td>
</tr>
<tr>
<td>In utero smoke exposure (exposed/not exposed)</td>
<td>5/55</td>
<td>7/95</td>
<td>.84</td>
</tr>
<tr>
<td>Birth type (vaginal/cesarean)</td>
<td>44/16</td>
<td>77/25</td>
<td>.77</td>
</tr>
<tr>
<td>Marital status (married or living together/divorced or single)</td>
<td>52/8</td>
<td>77/25</td>
<td>.55</td>
</tr>
<tr>
<td>Maternal education level, mean (SD)$^b$</td>
<td>5.01</td>
<td>5.16</td>
<td>.31</td>
</tr>
<tr>
<td>2- to 6-month-old infant regional MWF comparison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of participants</td>
<td>14</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Child feeding (breast/bottle/both)</td>
<td>5/6/3</td>
<td>7/5/10</td>
<td>.27</td>
</tr>
<tr>
<td>In utero smoke exposure (exposed/not exposed)</td>
<td>0/14</td>
<td>2/22</td>
<td>.16</td>
</tr>
<tr>
<td>Birth type (vaginal/cesarean)</td>
<td>10/4</td>
<td>18/4</td>
<td>.68</td>
</tr>
<tr>
<td>Marital status (married or living together/divorced or single)</td>
<td>10/4</td>
<td>19/3</td>
<td>.49</td>
</tr>
<tr>
<td>Maternal education level, mean (SD)$^b$</td>
<td>5.5</td>
<td>5.4</td>
<td>.42</td>
</tr>
<tr>
<td>6- to 22-month-old infant regional GMV comparison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of participants</td>
<td>23</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>Child feeding (breast/bottle/both)</td>
<td>8/7/8</td>
<td>9/10/17</td>
<td>.56</td>
</tr>
<tr>
<td>In utero smoke exposure (exposed/not exposed)</td>
<td>5/18</td>
<td>5/31</td>
<td>.19</td>
</tr>
<tr>
<td>Birth type (vaginal/cesarean)</td>
<td>19/4</td>
<td>26/10</td>
<td>.52</td>
</tr>
<tr>
<td>Marital status (married or living together/divorced or single)</td>
<td>18/5</td>
<td>27/9</td>
<td>.91</td>
</tr>
<tr>
<td>Maternal education level, mean (SD)$^b$</td>
<td>4.95</td>
<td>5.03</td>
<td>.16</td>
</tr>
</tbody>
</table>

*All groups were compared using a $\chi^2$ test.

$^b$Maternal education level was evaluated using the Education Scale of the Hollingshead Two-Factor Index of Social Position.35

Abbreviations: GMV, gray matter volume; MWF, myelin water fraction.
Brain Differences in Infants at Risk for AD

**ARTICLE INFORMATION**

Accepted for Publication: July 25, 2013.
Published Online: November 25, 2013.

**Author Affiliations:** Advanced Baby Imaging Lab, School of Engineering, Brown University, Providence, Rhode Island (Dean, O’Muircheartaigh, Dirks, Waskiewicz, Lehman, Deoni); Alpert Medical School of Brown University, Providence, Rhode Island (Jerskey); Banner Alzheimer’s Institute, Phoenix, Arizona (Chen, Protas, Thiyyagura, Roontiva, Fleisher, Reiman); Department of Mathematics, Arizona State University, Tempe (Chen); Department of Radiology, University of Arizona School of Medicine, Tucson (Chen); Arizona Alzheimer’s Consortium, Phoenix (Chen, Protas, Thiyyagura, Roontiva, Siniard, Fleisher, Huentelman, Reiman); Department of Neuroimaging, King’s College London, Institute of Psychiatry, London, England (O’Muircheartaigh); Department of Neurology, University of California, San Diego School of Medicine, San Diego (Fleisher); Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona (Siniard, Turk, Huentelman, Reiman); Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles School of Medicine, Los Angeles (Hua, Madsen, Thompson); Department of Psychiatry, University of Arizona School of Medicine, Phoenix (Reiman).

**Author Contributions:** Dr Deoni had access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Mr Dean and Drs Jerskey and Chen are shared first authors. Drs Deoni and Reiman are shared senior authors.

**Study concept and design:** Dean, Jerskey, Thompson, Fleisher, Deoni, Reiman.

**Acquisition of data:** Dean, Jerskey, Dirks, Waskiewicz, Lehman, Siniard, Turk, Huentelman, Deoni, Reiman.

**Drafting of the manuscript:** Dean, Jerskey, Dirks, Hua, Deoni.

**Critical revision of the manuscript for important intellectual content:** Dean, Chen, Protas, Thiyyagura, Roontiva, O’Muircheartaigh, Siniard, Turk, Hua, Madsen, Thompson, Fleisher, Huentelman, Deoni, Reiman.

**Statistical analysis:** Dean, Chen, Protas, Thiyyagura, Roontiva, O’Muircheartaigh, Hua, Deoni, Reiman.

**Obtained funding:** Huentelman, Deoni, Reiman.

**Administrative, technical, or material support:** Dean, Jerskey, Dirks, Waskiewicz, Lehman, Huentelman, Reiman, Deoni, Reiman.

**Study supervision:** Chen, Thompson, Huentelman, Deoni, Reiman.

**Conflict of Interest Disclosures:** None reported.

**Funding/Sponsor:** Funding for this study was provided by National Institutes of Mental Health grant R01 MH087510 (Dr Deoni), National Institute on Aging grants R01 AG031581 (Dr Reiman) and P30 AG169610 (Dr Reiman), the state of Arizona (Dr Reiman), Department of Defense, Air Force Office of Scientific Research National Defense Science and Engineering Graduate Fellowship 32 CFR 68a (Dr Madsen), and Sir Henry Wellcome Postdoctoral Fellowship 096195 (Dr O’Muircheartaigh).

**Role of the Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**REFERENCES**


The JAMA Neurology Editorial Board has benefited greatly by the presence of James A. Ferrendelli, MD, Houston, Texas, since 1997. After 17 years of contributing to the editorial life of the journal, he will be retiring. He has added great scholarship to our ongoing deliberations on the advisability to publish articles in epilepsy. His dedication to accuracy, detail, and precedent are legendary at our meetings and we are most grateful to him for these qualities, as well as his wonderful sense of humor and joy of doing neurology. Thank you, Jim, and all good wishes from all of us at JAMA Neurology.

Roger N. Rosenberg, MD, Editor